Delving into the Latest Updates on Beijing Dayspring Pharmaceutical Technology Co., Ltd with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Small molecule drug	1

Primary objective To evaluate the efficacy of CG2001 in treating Chinese adult male subjects with androgenetic alopecia (AGA) and determine the recommended dose for Phase III clinical trials. Secondary objective To evaluate the safety of CG2201 in treating Chinese adult male subjects with AGA at the target dose.

Start Date05 Dec 2024

Sponsor / Collaborator

Chenguang (Tianjin) Pharmaceutical Co., Ltd.

[+1]

NCT07076706

/ RecruitingPhase 2

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.

Start Date05 Dec 2024

Sponsor / Collaborator

Beijing Dayspring Pharmaceutical Technology Co., Ltd

CTR20243086

/ CompletedNot Applicable

盐酸非索非那定干混悬剂人体生物等效性研究

[Translation] Study on the bioequivalence of fexofenadine hydrochloride dry suspension in healthy volunteers

主要目的：采用单中心、随机、开放、两周期交叉、单剂量、空腹及餐后给药设计，比较辰光（天津）制药有限公司提供的盐酸非索非那定干混悬剂（30 mg）与サノフィ株式会社（赛诺菲株式会社）持证生产的盐酸非索非那定干糖浆（商品名：Allegra®，规格：30 mg）在中国健康人群中吸收程度和吸收速度的差异。次要目的：评价空腹及餐后条件下，辰光（天津）制药有限公司提供的盐酸非索非那定干混悬剂（规格：30 mg）与サノフィ株式会社（赛诺菲株式会社）持证生产的盐酸非索非那定干糖浆（商品名：Allegra®，规格：30 mg）的安全性。

[Translation]

Main purpose: A single-center, randomized, open, two-period crossover, single-dose, fasting and postprandial administration design was used to compare the differences in the degree and rate of absorption of fexofenadine hydrochloride dry suspension (30 mg) provided by Chenguang (Tianjin) Pharmaceutical Co., Ltd. and fexofenadine hydrochloride dry syrup (trade name: Allegra®, specification: 30 mg) produced by Sanofi Co., Ltd. in healthy Chinese people. Secondary purpose: Evaluate the safety of fexofenadine hydrochloride dry suspension (specification: 30 mg) provided by Chenguang (Tianjin) Pharmaceutical Co., Ltd. and fexofenadine hydrochloride dry syrup (trade name: Allegra®, specification: 30 mg) produced by Sanofi Co., Ltd. under fasting and postprandial conditions.

Start Date08 Sep 2024

Sponsor / Collaborator

Chenguang (Tianjin) Pharmaceutical Co., Ltd.

100 Clinical Results associated with Beijing Dayspring Pharmaceutical Technology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Beijing Dayspring Pharmaceutical Technology Co., Ltd

Login to view more data

100 Deals associated with Beijing Dayspring Pharmaceutical Technology Co., Ltd

Login to view more data

100 Translational Medicine associated with Beijing Dayspring Pharmaceutical Technology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Login to view more data